SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $428,195 | -39.1% | 29,490 | -12.2% | 0.20% | -38.5% |
Q2 2023 | $702,746 | +30.0% | 33,576 | +31.1% | 0.32% | -26.8% |
Q1 2023 | $540,756 | +13.9% | 25,604 | +37.2% | 0.44% | +56.0% |
Q4 2022 | $474,922 | -46.8% | 18,661 | -49.7% | 0.28% | -44.6% |
Q3 2022 | $892,000 | +6.3% | 37,104 | -3.2% | 0.51% | -23.8% |
Q4 2021 | $839,000 | -3.8% | 38,347 | -15.9% | 0.67% | +15.8% |
Q3 2021 | $872,000 | +6.2% | 45,584 | -4.7% | 0.58% | -0.9% |
Q2 2021 | $821,000 | +5.4% | 47,814 | +37.1% | 0.58% | +0.5% |
Q1 2021 | $779,000 | – | 34,873 | – | 0.58% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |